Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleA Randomized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain.
Author(s)Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S.
Journal, Volume, IssueJ Pain. 2008 Apr 8 [Epub ahead of print]
Major outcome(s)Significant improvement of pain

The Food and Drug Administration (FDA), Substance Abuse and Mental Health Services Administration (SAMHSA), and the National Institute for Drug Abuse (NIDA) report that no sound scientific studies support the medicinal use of cannabis. Despite this lack of scientific validation, many patients routinely use "medical marijuana," and in many cases this use is for pain related to nerve injury. We conducted a double-blinded, placebo-controlled, crossover study evaluating the analgesic efficacy of smoking cannabis for neuropathic pain. Thirty-eight patients with central and peripheral neuropathic pain underwent a standardized procedure for smoking either high-dose (7%), low-dose (3.5%), or placebo cannabis. In addition to the primary outcome of pain intensity, secondary outcome measures included evoked pain using heat-pain threshold, sensitivity to light touch, psychoactive side effects, and neuropsychological performance. A mixed linear model demonstrated an analgesic response to smoking cannabis. No effect on evoked pain was seen. Psychoactive effects were minimal and well-tolerated, but neuropsychological impairment was problematic, particularly with the higher concentration of study medication. PERSPECTIVE: This article presents the findings from a clinical trial examining the effect of smoking cannabis on neuropathic pain. Although this herbal medicine has analgesic properties, neuropsychological impairment was problematic and methods should be sought to diminish cognitive impairment before recommending medical marijuana to patients with neuropathic pain.

Dose(s)19-34 mg
Duration (days)3
Participants38 patients with neuropathic pain of different origin
DesignControlled study
Type of publicationMedical journal
Address of author(s)VA Northern California Health Care System, Department of Anesthesiology and Pain Medicine, University of California, Davis Medical Center, Davis, California.
Full text

[Back to Overview]  [IACM Homepage]